Phthalate ester toxicity in Leydig cells: developmental timing and dosage considerations

Ren-Shan Ge1, Guo-Rong Chen, Cigdem Tanrikut

  • 1Population Council and The Rockefeller University, 1230 York Avenue, New York, NY 10021, United States. rge@popcbr.rockefeller.edu

Insights

Phthalate exposure during pregnancy may harm male reproductive development. Studies show phthalates disrupt fetal Leydig cells, potentially causing testicular dysgenesis syndrome (TDS) in offspring.

Area of Science:

  • Endocrinology
  • Reproductive Toxicology
  • Environmental Health

Background:

  • Phthalates are common plasticizers with widespread human exposure.
  • Epidemiological studies link prenatal phthalate exposure to male reproductive issues, including genital malformations and impaired sperm production.
  • Testicular dysgenesis syndrome (TDS) is a condition characterized by reproductive dysfunction resulting from early fetal testicular disturbances.

Purpose of the Study:

  • To investigate the effects of phthalate exposure on fetal Leydig cells, key targets for phthalate toxicity.
  • To explore the association between phthalate-induced Leydig cell alterations and the development of testicular dysgenesis syndrome (TDS).

Main Methods:

  • Rodent models were used to study the impact of maternal phthalate exposure on fetal Leydig cell development and function.
  • Measurements included Leydig cell morphology, number, insulin-like growth factor 3 (INSL3) production, and steroidogenic capacity.

Main Results:

  • Prenatal phthalate exposure led to the formation of retained fetal Leydig cell clusters in male offspring.
  • Despite cluster retention, the number and volume of Leydig cells were reduced, along with suppressed INSL3 production and steroidogenic function.
  • These phthalate-induced changes in Leydig cells were associated with TDS features like cryptorchidism and impaired spermatogenesis.

Conclusions:

  • Phthalates disrupt fetal Leydig cell development and function, contributing to the etiology of testicular dysgenesis syndrome (TDS).
  • Targeting Leydig cells is crucial for understanding phthalate toxicity and its impact on male reproductive health.

Related Concept Videos

Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Toxicokinetics: Overview01:21

Toxicokinetics: Overview

Studies that assess how a drug is absorbed, distributed, metabolized, and excreted (ADME) at toxic doses are termed toxicokinetics. Understanding toxicokinetics helps predict adverse drug reactions (ADRs) and manage toxicity in humans.Toxicokinetics differs from pharmacokinetics mainly in the dose levels studied, with toxicokinetics focusing on higher toxic doses. The kinetics at these levels can be non-linear due to altered physiological processes. Toxicodynamics examines the relationship...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...